European Regulators Prepare the Pharma Industry for Future Changes as Legislation Is Formalized

The EU is focused on strengthening supply-chain resilience, avoiding medicine shortages, simplifying regulations, and implementing new approach methodologies.

Since July 2026, the European Union (EU) has shifted its focus from legislative reforms to practical applications, prioritizing supply-chain resilience, preventing medicine shortages, streamlining regulations, artificial intelligence (AI) governance, and introducing innovative approaches for nonclinical drug development.

Related to this article

October 1st, 2026

Drapeau’s AI Deep Dive: The Control Lab Tested for Flavor

Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.

October 1st, 2026

Q&A: USP CEO Urges Manufacturers to Act Now to Stop Drug Shortages

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

September 30th, 2026

CPHI Milan: Why One Reliable Supplier Isn't Enough

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com

September 28th, 2026

CPHI Milan 2026: Digital Supply Chains

Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.

FDA approves once-daily tavapadon, the first selective D1/D5 agonist for adults with Parkinson's

September 28th, 2026

Tavapadon Sets Development Benchmark for Parkinson's

FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.

Merck's $2.13B KRAS G12D license moves tech transfer and supply planning into the preclinical stage.

September 28th, 2026

KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer

Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.

September 28th, 2026

CPHI Milan: How USP Will Shape Procurement Decisions

Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.

September 25th, 2026

PharmTech’s Weekly Roundup—September 25, 2026

Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.